FSKR yields 10.20% · PFE yields 6.13%● Live data
📍 FSKR pulled ahead of the other in Year 1
Combined, FSKR + PFE cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of FSKR + PFE for your $10,000?
FS KKR Capital Corp. II, formerly known as FS Investment Corp II, is a business development company specializing in investments in floating rate, senior secured loans-first lien and second line, senior secured bonds, subordinated debt, collateralized securities, corporate bonds, debt securities, equity such as warrants or options in middle market private companies. The fund does not intend to invest to any significant degree in start-up companies, turnaround situations or companies with speculative business plans. It seeks to invest in various sectors such as consumer services, energy, capital goods, software and services, telecommunication services, consumer durables and apparel, diversified financials, materials, automobiles and components, commercial and professional services, media, technology hardware and equipment, health care equipment and services, insurance, retailing, transportation, pharmaceuticals, biotechnology, and life sciences, food and staples retailing, food, beverage, and tobacco, household and personal products, real estate, and utilities. The fund seeks to invest in private companies based in the United States. It also invests in non-U.S. securities, which may include securities denominated in U.S. dollars or in non-U.S. currencies, to the extent permitted by the 1940 Act. The fund purchase interests in loans through secondary market transactions in the ?over-the-counter? market for institutional loans or directly from our target companies. It also purchase minority interests in the form of common or preferred equity in target companies, either in conjunction with one of its debt investments or through a co-investment with a financial sponsor, such as an institutional investor or private equity firm. It may have board representation or board observation rights in its portfolio companies.
Full FSKR Calculator →Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Full PFE Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.